Monoclonal Antibody to Phosphorylated p53

Inventors:    L. Otvos, H. Ertl, M. Thurin, and R. Hoffman

Tech ID:    OL-98001

Description: The gene for the tumor suppressor protein p53 encodes a nuclear phosphoprotein that is altered by mutation or deletion in about 50% of human tumors. When single point mutations modify p53 structure and function, post-translational modifications of mutated p53 molecules are expected to interfere even more strongly with its function of controlling cell growth and division. The most prominent post-translational modification of p53 is phosphorylation at one or more of many sites along the protein. Wistar researchers developed a double-phosphorylated peptide that is phosphorylated at the Ser378 and Ser392 sites of human p53. This peptide was then used to generate a highly sensitive monoclonal antibody (mAb p53-18) to p53 protein. This antibody can be used to distinguish the phosphorylated from the non-phosphorylated forms of p53. Since sera from cancer patients preferentially label the double-phosphorylated p53 peptide, the mAb p53-18 may be useful in developing cancer diagnostics.

Keywords: Monoclonal Antibody, research tool, diagnostic, immunoassay, research reagent, cancer, western blotting

Isotype: Igm

Applications and Advantages: mAb p53-18 is a useful reagent for cancer research.

Intellectual Property Status: A US patent application has been filed on production and uses of antibodies to multi-phosphorylated p53. International patent applications are pending.

Licensing Opportunity: mAb p53-18 is available for non-exclusive license for research reagent use.

Contact:

Meryle J. Melnicoff, Ph.D.
Director, Business Development The Wistar Institute
Phone: (215) 898-0049
melnicoff@wistar.org